| Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) (NCT05446870) | Merck Sharp & Dohme LLC | 2022-07-25 |
| A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) (NCT05429970) | Memorial Sloan Kettering Cancer Center | 2022-06-17 |
| Evaluation of Pretreatment Sarcopenia in Patients With Inoperable High-grade Ovarian Carcinoma as Part of Optimised Management (NCT05415527) | Institut Bergonié | 2022-06-11 |
| Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors (NCT05194735) | Alaunos Therapeutics | 2022-04-04 |
| Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy (NCT04997096) | Dana-Farber Cancer Institute | 2022-04-02 |
| Niraparib Plus Anlotinib for Recurrent Ovarian Cancer (NCT05311579) | Lei Li | 2022-03-27 |
| A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer (NCT05200364) | Sutro Biopharma, Inc. | 2022-03-22 |
| Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device (NCT06789224) | Lindis Bloodcare GmbH | 2022-02-15 |
| IOTA Ultrasound Criteria and Serum CA 125 for Ovarian Malignancy Detection (NCT06977334) | Maharajgunj Medical Campus | 2022-01-01 |
| HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics (NCT04905082) | City of Hope Medical Center | 2021-12-30 |
| Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study (NCT05180851) | Shanghai Fengxian District Central Hospital | 2021-11-30 |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors (NCT04851119) | Children's Oncology Group | 2021-11-08 |
| Milademetan in Advanced/Metastatic Solid Tumors (NCT05012397) | Rain Oncology Inc | 2021-11-01 |
| Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing (NCT04981119) | A2 Biotherapeutics Inc. | 2021-10-29 |
| A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) (NCT05001282) | Elucida Oncology | 2021-09-13 |
| ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer (NCT04602117) | QuantumLeap Healthcare Collaborative | 2021-07-28 |
| A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours (NCT04969835) | Avacta Life Sciences Ltd | 2021-07-16 |
| Prospective Study of Immune Alterations in Operable Breast and Ovarian Carcinoma (NCT04562623) | Centre Leon Berard | 2021-07-01 |
| A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors (NCT04686682) | Jacobio Pharmaceuticals Co., Ltd. | 2021-05-07 |
| A Study of Intra-operative Imaging in Women With Ovarian Cancer (NCT04878094) | Memorial Sloan Kettering Cancer Center | 2021-05-03 |
| Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses. (NCT05610501) | Universitaire Ziekenhuizen KU Leuven | 2021-05-01 |
| Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors (NCT04917744) | Mayo Clinic | 2021-04-01 |
| Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors (NCT04628780) | Pfizer | 2020-12-16 |
| National Cancer Institute "Cancer Moonshot Biobank" (NCT04314401) | National Cancer Institute (NCI) | 2020-11-11 |
| Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous Recombination Deficiency (NCT06827353) | Centre Hospitalier Universitaire de Nīmes | 2020-10-01 |
| A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (NCT04251052) | NRG Oncology | 2020-09-01 |
| A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors (NCT04442126) | Numab Therapeutics AG | 2020-08-19 |
| Clinical Outcomes for Offering Genetic Testing in a Tiered Approach (NCT04902144) | Fred Hutchinson Cancer Center | 2020-08-03 |
| A Trial Evaluating TG4050 in Ovarian Carcinoma. (NCT03839524) | Transgene | 2019-12-09 |
| Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives (NCT04257045) | M.D. Anderson Cancer Center | 2019-08-21 |
| Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI) (NCT03842982) | Centre Oscar Lambret | 2019-05-03 |
| Dietary Magnesium in Preventing Low Blood Magnesium Levels in Patients With Ovarian Cancer Receiving Carboplatin Chemotherapy (NCT04310826) | M.D. Anderson Cancer Center | 2019-04-23 |
| Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy (NCT03382574) | National Cancer Institute (NCI) | 2019-03-14 |
| Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers (NCT03748186) | Sutro Biopharma, Inc. | 2019-02-01 |
| Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF (NCT03604315) | M.D. Anderson Cancer Center | 2018-12-18 |
| Circulating Tumor DNA as an Early Marker of Recurrence and Treatment Efficacy in Ovarian Carcinoma (NCT03302884) | Institut Paoli-Calmettes | 2018-10-10 |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors (NCT03517488) | Xencor, Inc. | 2018-07-10 |
| NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma (NCT06972693) | European Institute of Oncology | 2018-06-12 |
| Real-World Effectiveness of PLD in Platinum- Sensitive Recurrent Ovarian Cancer (NCT03562533) | Konkuk University Medical Center | 2018-05-17 |
| PET/MR Versus CECT Scans in Imaging Patients With Ovarian Cancer or Highly Suspected Ovarian Cancer (NCT03965481) | M.D. Anderson Cancer Center | 2018-05-12 |
| Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors (NCT03372720) | Ohio State University Comprehensive Cancer Center | 2018-05-11 |
| EHealth Mindful Movement and Breathing in Improving Outcomes in Participants Undergoing Gynecologic Surgery (NCT03379376) | Wake Forest University Health Sciences | 2018-04-05 |
| 68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer (NCT03857087) | University of California, San Francisco | 2018-04-02 |
| Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2 (NCT03296826) | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | 2017-11-08 |
| Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer (NCT03180294) | NRG Oncology | 2017-05-31 |
| Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. (NCT03085225) | Institut Bergonié | 2017-05-05 |
| An Exercise Intervention Trial to Reduce Symptoms & Improve Clinical Outcomes of Platinum-Based Treatment in Ovarian Cancer Patients (NCT02878980) | City of Hope Medical Center | 2016-09-02 |
| Photoacoustic Imaging in Detecting Ovarian or Fallopian Tube Cancer (NCT02530606) | Stanford University | 2016-09-01 |
| Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer (NCT02708511) | Sanjiv Sam Gambhir | 2016-08-01 |
| Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer (NCT02345265) | National Cancer Institute (NCI) | 2016-05-23 |
| HE4 as a Relapse Biomarker in Ovarian Cancers (NCT02595281) | Institut de Cancérologie de Lorraine | 2016-04-01 |
| Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (NCT02584478) | Advenchen Laboratories, LLC | 2015-12-01 |
| REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression (NCT02584465) | ARCAGY/ GINECO GROUP | 2015-08-28 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCT02465060) | National Cancer Institute (NCI) | 2015-08-17 |
| Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma (NCT02487693) | The First People's Hospital of Changzhou | 2015-07-01 |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (NCT02419495) | M.D. Anderson Cancer Center | 2015-06-26 |
| Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies (NCT02578888) | Albert Einstein College of Medicine | 2015-04-01 |
| Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery (NCT02315469) | NRG Oncology | 2015-02-10 |
| Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma (NCT02297958) | Rennes University Hospital | 2015-01-15 |
| DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission (NCT02166905) | Roswell Park Cancer Institute | 2014-10-10 |
| Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members (NCT02194387) | M.D. Anderson Cancer Center | 2014-09-17 |
| Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE) (NCT02244502) | NovoCure Ltd. | 2014-09-01 |
| LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma (NCT02083536) | University of Miami | 2014-05-01 |
| Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies (NCT02025985) | Karyopharm Therapeutics Inc | 2014-04-09 |
| HOT: HIPEC in Ovarian Cancer as Initial Treatment (NCT02124421) | Mercy Medical Center | 2014-04-01 |
| (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma (NCT01936974) | Western Regional Medical Center | 2013-09-01 |
| Prophylactic Salpingectomy With Delayed Oophorectomy (NCT01907789) | M.D. Anderson Cancer Center | 2013-08-26 |
| Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma (NCT01519869) | Rachel Miller | 2012-03-01 |
| Whole-body Diffusion MRI for Staging, Response Prediction and Detecting Tumor Recurrence in Patients With Ovarian Cancer (NCT01657747) | Universitaire Ziekenhuizen KU Leuven | 2011-11-01 |
| Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction (NCT01366144) | National Cancer Institute (NCI) | 2011-06-20 |
| Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT01295489) | Gynecologic Oncology Group | 2011-03-01 |
| Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer (NCT01312376) | Abramson Cancer Center at Penn Medicine | 2011-03-01 |
| Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 (NCT01445275) | Gynecologic Oncology Group | 2011-01-01 |
| Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy (NCT01175772) | HaEmek Medical Center, Israel | 2010-08-01 |
| Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy (NCT01709487) | Jules Bordet Institute | 2010-05-01 |
| Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer (NCT01091428) | Millennium Pharmaceuticals, Inc. | 2010-04-16 |
| Bioequivalence Study of SPARC147609 in Patients With Ovarian Cancer (NCT00862355) | Sun Pharma Advanced Research Company Limited | 2010-03-01 |
| Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT00989651) | National Cancer Institute (NCI) | 2009-10-28 |
| Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies (NCT02073500) | Oslo University Hospital | 2009-09-01 |
| MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma (NCT00853307) | Millennium Pharmaceuticals, Inc. | 2009-03-23 |
| A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma (NCT01481701) | Jules Bordet Institute | 2008-10-01 |
| Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors (NCT00756847) | Sanofi | 2008-09-01 |
| Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer (NCT00679783) | AstraZeneca | 2008-07-08 |
| Green Tea Intake for the Maintenance of Complete Remission in Women With Advanced Ovarian Carcinoma (NCT00721890) | CHU de Quebec-Universite Laval | 2008-06-01 |
| Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma (NCT00868192) | Washington University School of Medicine | 2008-05-01 |
| Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer (NCT00445887) | Gynecologic Oncology Group | 2008-03-10 |
| Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression (NCT00659399) | NYU Langone Health | 2008-01-01 |
| A Phase I Study of Intraperitoneal Hyperthermic Docetaxel (NCT00474669) | University of Louisville | 2007-06-01 |
| A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen (NCT00623831) | Ludwig Institute for Cancer Research | 2007-05-01 |
| Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors (NCT00488878) | M.D. Anderson Cancer Center | 2006-05-19 |
| Doxil and Gemcitabine in Recurrent Ovarian Cancer (NCT00312650) | Women and Infants Hospital of Rhode Island | 2006-04-01 |
| Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries (NCT00305695) | Gynecologic Oncology Group | 2005-11-28 |
| Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin (NCT00181701) | Massachusetts General Hospital | 2004-10-01 |
| Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma (NCT01689714) | Endocyte | 2003-08-01 |
| Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma (NCT00183794) | University of Southern California | 2002-11-01 |
| Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer (NCT00214058) | University of Wisconsin, Madison | 2002-08-01 |
| Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study (NCT00715286) | All India Institute of Medical Sciences | 2001-11-01 |
| Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer (NCT00047632) | InterMune | 2001-10-01 |
| Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial) (NCT01696994) | National Cancer Institute (NCI) | 1993-11-16 |